Wireless, Intermittent Monitoring of Right Heart Pressures in HF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the trial is to evaluate the wireless monitoring of pulmonary artery pressure using the CardioMEMS HF Pressure Measurement System in adult subjects with NYHA Class III Heart Failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

NCT04398654

Heart Failure

RECRUITING NA

Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)

NCT04078243

Pulmonary Hypertension

RECRUITING

Non-invasive Pulmonary Artery Prediction

NCT05622695

Heart Failure Pulmonary Arterial Hypertension

UNKNOWN

Physiological Signals, Activity and Posture for Surface Mounted Insertable Cardiac Monitor in Heart Failure Study

NCT04112576

Heart Failure, Systolic Heart Failure, Diastolic

COMPLETED

Clinical Impact of Non-invasive Hemodynamic Monitoring

NCT02950597

Heart Failure

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is designed to demonstrate that the CardioMEMS Sensor can be positioned in the right or left pulmonary artery, and that Sensor pressure measurements correlate to standardized methods of intra-cardiac pressure measurements post-sensor implant and at the 60 day visit. Safety will be monitored by the occurrence of adverse events throughout the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NYHA Class III Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pressure Measurement System

CardioMEMS HF Pressure Measurement System

Group Type EXPERIMENTAL

CardioMEMS HF Pressure Measurement System

Intervention Type DEVICE

Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CardioMEMS HF Pressure Measurement System

Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is male or female, at least 18 years of age
2. Subjects of childbearing age who have a negative serum pregnancy test, and at screening have agreed to use a reliable mechanical or hormonal form of conception during the study.
3. Subject has a diagnosis of New York Heart Association (NYHA) Class III HF at screening and at baseline.
4. Subject is able and willing to provide written informed consent or the subject guardian is able and willing to provide informed consent.
5. Subject has life expectancy of 1-2 years.

Exclusion Criteria

1. Subject has unstable medical condition or impairment other than a medical condition associated with HF which would significantly increase the subject's morbidity or mortality risk.
2. Subject is unable to tolerate a right heart catheterization.
3. Subject is planned to undergo a heart transplantation or cardiac surgery within 2 months after enrollment.
4. Subject has permanent indwelling central venous catheter.
5. Subject has history of myocardial infarction (MI), unstable angina, stroke, transient ischemic attack, or intractable arrhythmias within last 2 months.
6. Subject has history of congenital heart disease or prosthetic valve on right side.
7. Subject has unstable hypertension.
8. Subject has a known coagulability disease state.
9. Subject has a known hypersensitivity and/or allergy to aspirin and clopidogrel.
10. Subject has active lung infection or acute pulmonary decompensation.
11. Subject has elevated white blood cell count and signs of infection are evident.
12. Subject has chronic renal insufficiency as defined by serum creatinine of greater than or equal to 2 mg/dl or requirement for dialysis.
13. Subject who is pregnant or lactating or might become pregnant during the duration of the study.
14. Subject who is participating in another therapeutic interventional trial.
15. Subject has other medical, psychological, or social circumstances that may affect the ability to comply with the study requirements or increase risk to the subject.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No